Search results
Added:
1 month ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants…
View more
Added:
10 months ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes…
View more
Added:
1 year ago
Added:
2 months ago
Added:
5 months ago
AHA Conference 2024 - In this highlights video from AHA 2024, Dr Michelle Kittleson (Cedars-Sinai California Heart Center, US) offers a concise and insightful summary of the most influential late-breaking trials presented at the conference. Dr Kittleson discusses the pivotal studies poised to impact clinical practice and enhance patient outcomes in heart failure care.Trials covered in detail…
View more
Added:
7 months ago
HFSA Congress 2024 - Dr Mark Ricciardi (NorthShore Cardiovascular Institute, US) joins us to discuss the findings from the EXPANDed real-world clinical trial on mitral transcatheter edge-to-edge repair with the MitraClip System.The study is designed to confirm the safety and performance of the MitraClip NTR and XTR Systems in mTEER procedures. 1000 patients across 60 sites in Europe and the US…
View more
Added:
1 year ago
AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.Trials discussed in detail include:SELECT: Semaglutide and Cardiovascular Outcomes in Obesity…
View more
Added:
1 year ago
AHA 23 — Dr Purvi Parwani, cardiologist and multimodality imager, and director of the Women's Heart Clinic at Loma Linda University Health in the US, spotlights three game-changing late-breaking science trials from the AHA Scientific Sessions. Discover the trials anticipated to reshape clinical practices as Dr Parwani shares her insights.Trials discussed in detail include:POP-HT: Cardiac…
View more
Added:
1 year ago
HFA 23 - In this short interview, Prof Martin Cowie (Clinical Vice-President AstraZeneca R&D & Honorary Consultant Cardiologist, Guy’s & St Thomas’ NHS Foundation Trust, London, UK) joins us to discuss the findings from a prespecified analysis of the DELIVER trial which covered the characteristics, outcomes and effects of dapagliflozin according to the duration of heart failure.
DELIVER was…
View more
